Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
Stocks in this Quantisnow insightHealth Care
Historical context for AMRX
Across the 23 sessions after earlier AMRX headlines, the stock closed higher 12 times and lower 11 times, with a median move of 2.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | AMRX | SPY |
|---|---|---|---|
| Jun 4, 2026 | Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution | +5.0% | +0.4% |
| Jun 1, 2026 | Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026 | -2.1% | +0.3% |
| May 8, 2026 | Amneal Reports First Quarter 2026 Financial Results | -3.8% | +0.8% |
| Apr 22, 2026 | Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leaderand 1 other headline that session | -1.5% | +1.0% |
| Apr 20, 2026 | Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson's Disease, Including Over 3 More Hours of Daily "Good On" Time When Switching from RYTARY® | -4.7% | -0.2% |
| Apr 17, 2026 | UBS initiated coverage on Amneal Pharmaceuticals with a new price target | +6.3% | +1.2% |
Quantisnow market dataNASDAQ
AMRX
Amneal Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for AMRX
Full AMRX profile on Quantisnow Follow AMRX and get a push notification the moment its next story breaks.